Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for systemic use. It selectively blocks BCR‑ABL, KIT and PDGFR kinases, providing therapeutic benefit in chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality‑assured product availability for qualified healthcare providers. The company adheres to EU GMP standards and provides regulatory documentation to support import and clinical use.

Nilotinib is indicated for hematologic malignancies driven by the BCR‑ABL tyrosine‑kinase pathway. - Chronic myeloid leukemia (chronic phase): provides disease control and prolongs survival in adult patients. - Chronic myeloid leukemia (accelerated or blast phase): helps achieve hematologic and cytogenetic responses when other therapies are insufficient. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: contributes to remission induction and maintenance in adult patients.

Nilotinib may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Rash: mild skin eruptions or itching. - Nausea: occasional upset stomach or vomiting. - Diarrhea: loose stools that may be watery. - Fatigue: general tiredness or weakness. - Elevated liver enzymes: mild increases in ALT/AST. - Myalgia: muscle aches or soreness.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, myocardial infarction, or arterial occlusion. - Severe hepatotoxicity: marked elevation of liver enzymes or hepatitis. - Pancreatitis: abdominal pain with elevated pancreatic enzymes. - QT interval prolongation: cardiac rhythm disturbance that may lead to arrhythmia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood dyscrasias: neutropenia, thrombocytopenia, or anemia.

Prior to initiating Nilotinib, clinicians should evaluate several safety considerations to minimize risk. - Cardiac assessment: obtain baseline ECG and monitor for QT prolongation. - Hepatic function: check liver enzymes and adjust use in patients with liver impairment. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks. - Monitoring: perform regular complete blood counts and metabolic panels during therapy. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Nilotinib can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce Nilotinib exposure. - QT‑prolonging agents (e.g., amiodarone, fluoroquinolones): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Nilotinib levels, requiring dose adjustment. - Antacids or proton‑pump inhibitors: can affect absorption; separate dosing by at least 2 hours. - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for increased statin exposure and muscle toxicity. - Herbal supplements (e.g., St. John’s wort): may lower drug concentrations.